PFE - Immunome: AL102 And Other Established Protein Targets Could Drive Value
2024-06-27 14:14:36 ET
Summary
- Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025.
- The global desmoid tumor market is projected to grow to $5.49 billion by 2032.
- IM-1021 is an antibody-drug conjugate being developed to target ROR1 expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025.
- IM-3050 is a radio-ligand therapy being developed to target FAP expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025.
Immunome, Inc. ( IMNM ) is an interesting biotech to consider, and that's because it has various therapy types it deploys for its pipeline. One of the lead assets it has is AL102, which is being explored in the ongoing phase 3 RINGSIDE study for the treatment of patients with desmoid tumors. Enrollment for Part B of this study was completed back in February 2024 and data from this is expected to be released in the 2nd half of 2025.
The truth is that AL102, along with AL101, were two clinical assets acquired from Ayala Pharmaceuticals ( ADXS ). Should phase 3 clinical testing go well for Immunome in advancing the use of AL102 for the treatment of patients with desmoid tumors, then it is highly likely that it might even be in a position to file a New Drug Application [NDA] for this program in 2025 as well....
Immunome: AL102 And Other Established Protein Targets Could Drive Value